Form 8-K - Current report:
SEC Accession No. 0001437749-25-014405
Filing Date
2025-05-05
Accepted
2025-05-05 08:30:07
Documents
18
Period of Report
2025-05-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vxrt20250503_8k.htm   iXBRL 8-K 32034
2 EXHIBIT 99.1 ex_811297.htm EX-99.1 16777
3 EXHIBIT 99.2 ex_811298.htm EX-99.2 20323
8 image1.jpg GRAPHIC 5866
9 image2.jpg GRAPHIC 1869
  Complete submission text file 0001437749-25-014405.txt   232564

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vxrt-20250505.xsd EX-101.SCH 3579
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vxrt-20250505_def.xml EX-101.DEF 11424
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE vxrt-20250505_lab.xml EX-101.LAB 15310
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vxrt-20250505_pre.xml EX-101.PRE 11584
20 EXTRACTED XBRL INSTANCE DOCUMENT vxrt20250503_8k_htm.xml XML 2842
Mailing Address 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080 (650) 550-3500
Vaxart, Inc. (Filer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35285 | Film No.: 25911147
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)